235 related articles for article (PubMed ID: 29279596)
1. Light chain multiple myeloma: an evaluation of its biochemical investigations.
Zahari Sham SY; C Thambiah S; Samsudin IN; Lim SM
Malays J Pathol; 2017 Dec; 39(3):311-315. PubMed ID: 29279596
[TBL] [Abstract][Full Text] [Related]
2. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
3. Light chain myeloma: A brief report from India.
Singh N; Agrawal N; Sekhri R; Mehta A; Kumar D; Vishwakarma G; Ahmed R; Bhurani D
Indian J Pathol Microbiol; 2019; 62(3):441-444. PubMed ID: 31361235
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: from diagnosis to treatment.
Eslick R; Talaulikar D
Aust Fam Physician; 2013 Oct; 42(10):684-8. PubMed ID: 24130968
[TBL] [Abstract][Full Text] [Related]
6. Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma.
Kishi S; Obata F; Miki H; Matsuura M; Nishimura K; Tamaki M; Kishi F; Murakami T; Abe H; Nagai K; Abe M; Doi T
Intern Med; 2018 Dec; 57(24):3597-3602. PubMed ID: 30101939
[TBL] [Abstract][Full Text] [Related]
7. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
Bladé J; Kyle RA
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1259-72. PubMed ID: 10626149
[TBL] [Abstract][Full Text] [Related]
8. Association between left ventricular function and paraprotein type in patients with multiple myeloma.
Yi JE; Lee SE; Jung HO; Min CK; Youn HJ
Korean J Intern Med; 2017 May; 32(3):459-468. PubMed ID: 27048256
[TBL] [Abstract][Full Text] [Related]
9. [Light chain myeloma: clinical study and prognostic factors ].
Redón J; Caballero M; Herranz C
Med Clin (Barc); 1982 Jun 16-30; 79(2):54-8. PubMed ID: 6811809
[No Abstract] [Full Text] [Related]
10. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency.
Park JW; Kim YK; Bae EH; Ma SK; Kim SW
Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879
[TBL] [Abstract][Full Text] [Related]
11. The importance of urinary immunoglobulin light chain isoelectric point (pI) in nephrotoxicity in multiple myeloma.
Coward RA; Delamore IW; Mallick NP; Robinson EL
Clin Sci (Lond); 1984 Feb; 66(2):229-32. PubMed ID: 6420108
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin heavy and light chain isotypes in multiple myeloma patients.
Ansari NA; Owais M; Usha
Asian Pac J Cancer Prev; 2007; 8(4):593-6. PubMed ID: 18260735
[TBL] [Abstract][Full Text] [Related]
14. Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.
Chen J; Fang M; Zhao YP; Yi CH; Ji J; Cheng C; Wang MM; Gu X; Sun QS; Chen XL; Gao CF
PLoS One; 2015; 10(6):e0127022. PubMed ID: 26075387
[TBL] [Abstract][Full Text] [Related]
15. Trifecta of light chain cast nephropathy, monoclonal plasma cell infiltrates, and light chain proximal tubulopathy.
Koratala A; Ejaz AA; Hiser WM; Clapp WL
Kidney Int; 2017 Dec; 92(6):1559. PubMed ID: 29153147
[No Abstract] [Full Text] [Related]
16. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
17. Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review.
Gu H; Lee WI; Jeon Y; Kang SY; Kim MH; Park TS
Clin Lab; 2017 Feb; 63(2):373-378. PubMed ID: 28182355
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
19. Gamma A myeloma with hyperviscosity and obstructive uropathy.
Roth RM; Glovsky MM; Cooper JF; Douglas SD
J Urol; 1977 Apr; 117(4):527-9. PubMed ID: 321814
[TBL] [Abstract][Full Text] [Related]
20. How lab staff and the estimation of free light chains can combine to aid the diagnosis of light chain disease.
Sinclair D; Wainwright L
Clin Lab; 2007; 53(5-6):267-71. PubMed ID: 17605400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
